Biovista initiates project on adverse events profiling and drug repositioning.

January 5, 2007Announcements

Biovista began work today on one clinical candidate and one pre-clinical candidate on behalf of a major Cambridge, MA biotechnology company. The aim is to elucidate adverse events profiles and repositioning opportunities using Biovista’s proprietary development platform. By defining the adverse events profile, the design of the clinical trial and choice of specific compounds will … Read More